Skip to main content

In Vitro Diagnostics Market to Reach USD 87.11 Billion by 2026; Increasing Prevalence of Cancer Will Enable Growth, says Fortune Business Insights

Written by Customer Service on . Posted in Mergers And Acquisitions.

Pune, Aug. 20, 2020 (GLOBE NEWSWIRE) — According to the report, the global In Vitro Diagnostics Market was valued at USD 61.22 Billion in 2018 is predicted to reach USD 87.11 Billion by 2026, exhibiting a CAGR of 4.5% during the forecast period.Introduction of new techniques for disease diagnosis is a key factor driving the market, states Fortune Business Insights in a report, titled “In Vitro Diagnostics Market Size, Share & Industry Analysis, By Product Type (Instruments, Reagents & Consumables), By Technique (Immunodiagnostics, Clinical Chemistry, Molecular Diagnostics, Point of Care, Hematology and Others), By Application (Infectious Diseases, Cardiology, Oncology, Gastroenterology, Others), By End User (Clinical Laboratories, Hospitals, Physicians Offices, Others) and Regional Forecast, 2019-2026.”As per the report published by Fortune Business Insights, the reagents and consumables segment is expected to hold maximum shares in the global-vitro diagnostics market during the forecast period owing to the increasing research and development activities for the diagnosis of chronic diseases.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/in-vitro-diagnostics-ivd-market-101443
In addition, the escalating demand for self-test and point-of-care devices will subsequently increase the demand for reagents and consumables segment, which, will, in, turn boost the global In Vitro Diagnostics Market revenue during the forecast period.The other highlights of the report include:•              Targeted analysis of the impact of COVID-19 on the market;•              Detailed study of the factors, trends, and constraints shaping the market;•              Careful evaluation of the regional dynamics influencing the market; and•              Thorough profiling and examination of the key market players and their strategies.The global economy is in absolute turmoil because of the COVID-19 pandemic outbreak. Some industries remain largely unaffected by the outbreak, some are thriving, but most are in doldrums. Although the healthcare industry is flourishing, certain markets within the industry are experiencing staggered growth. Wading through these troubled times is a difficult task and Fortune Business Insights™ aims at equipping your business with the most comprehensive market insights, collated and analyzed by our expert and experienced research team.
Click here to get the short-term and long-term impact of COVID-19 on this market.Please visit: https://www.fortunebusinessinsights.com/industry-reports/in-vitro-diagnostics-ivd-market-101443
Increasing Prevalence of Chronic and Infectious Disease Will Enable GrowthThe launch of diagnostic and rapid testing tools by leading market players will propel growth of the global In Vitro Diagnostics Market. For instance, Thermo Fisher Scientific launched Phadia 200 for diagnosis of allergy & autoimmune conditions. The launch of Phadia 200 is anticipated to increase the revenue of the company.According to the report, the reagents and consumables segment will account for a major portion in the global In Vitro Diagnostics Market during the forecast period owing to the adoption of self- test and point-of-care devices. Furthermore, the instrument segment is likely to grow at a moderately slower pace during the forecast period. Rising technological advancement is predicted to aid growth of the segment.Moreover, the increasing cases of cancer and infectious disease around the world will further accelerate global In Vitro Diagnostics Market growth.
Quick Buy –  In Vitro Diagnostics Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/101443
Launch of Altostar Molecular Diagnostics Workflow Will Boost GrowthAltona Diagnostics GmbH, molecular diagnostic testing solutions company launched a CE-IVD marked AltoStar Molecular Diagnostics Workflow. AltoStar Molecular Diagnostics a flexible and efficient automatic system that automates the entire workflow from sample preparation up to analysis.Fortune Business Insights states the launch of CE-IVD marked AltoStar Molecular Diagnostics Workflow is expected to boost the In Vitro Diagnostics Market revenue. Furthermore, the oncology segment is likely to grow at a considerable rate during the forecast period.Rising adoption and availability of advanced home care kits such as fecal occult blood test (FOBT) for diagnosis of colon cancer in homecare settings is one of the major factor likely to fuel demand for the oncology segment, which, will, in turn, uplift the global In Vitro Diagnostics Market sharesThe Major Companies In The Global In Vitro Diagnostics Market Include:F. Hoffmann-La Roche LtdAbbottSiemensThermo Fisher Scientific Inc.DanaherBio-Rad Laboratories, Inc.QIAGENSysmex CorporationQuest Diagnostics IncorporatedOther Prominent Players
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/in-vitro-diagnostics-ivd-market-101443
Market Segmentations:By Product Type•              Instruments•              Reagents & ConsumablesBy Technique•              Immunodiagnostics•              Clinical Chemistry•              Molecular Diagnostics•              Point of Care•              Hematology•              OthersBy Application•              Infectious Diseases•              Cardiology•              Oncology•              Gastroenterology•              OthersBy End User•              Clinical Laboratories•              Hospitals•              Physician’s Offices•              OthersBy Geography•              North America (U.S. and Canada)•              Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)•              Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)•              Latin America (Brazil, Mexico, and Rest of Latin America)•              Middle East & Africa (South Africa, GCC and Rest of Middle East & Africa)
Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/in-vitro-diagnostics-ivd-market-101443
Have a Look at Related Reports:Next-Generation Sequencing (NGS) Market Share and Global Trend By Type (Products, Instruments & Software, Consumables, Services), By Application (Diagnostics, Research), By End User (Research Institutes, Healthcare Facilities & Diagnostic Centres, Pharmaceutical & Biotechnological Companies, Contract Research Organization) & Geography Forecast till 2026U.S. Biosimilars Market Share and Global Trend By Drug Class (Filgrastim & Pegfilgrastim, Monoclonal Antibodies, Others), By Disease Indication (Cancer, Autoimmune Diseases, Others) By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) and Geography Forecast till 2026Point of Care (POC) Diagnostics Market Share and Global Trend By Product (Blood Glucose Monitoring, Infectious Diseases, Cardiometabolic Diseases, Pregnancy and Fertility Testing Products, Hematology Testing Products, Others), By End User (Hospitals Bedside, Physician’s Office Lab, Urgent Care & Retail Clinics, Home and Self Testing) and Geography Forecast till 2026Blood Glucose Meters Market Share and Global Trend by Product (Continuous Glucose Monitoring Devices, Self-Monitoring Blood Glucose (SMBG) Systems), By Technique (Invasive, Non-Invasive), By Type (Wearable, Non-Wearable), By Distribution Channel (Institutional Sales, Retail Sales) and Geography forecast 2026Immunodiagnostics Market Share and Global Trend By Product Instruments, Reagents & Consumables), By Application (Oncology & Endocrinology, Hepatitis & Retrovirus, Cardiac Markers, Infectious Diseases), By End user (Clinical Laboratories, Hospitals, Physician’s Offices), By End-user(Hospitals, Dental Clinics, Academic & Research Institutes) and Geography Forecast till 2026
About Us:Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com 
Fortune Business Insights™
LinkedIn | Twitter | Blogs
Press Release: https://www.fortunebusinessinsights.com/press-release/in-vitro-diagnostics-market-9278

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.